Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
FKHR/FOXO1 Double Nickase Plasmid (h): sc-400137-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- FKHR/FOXO1 Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- FKHR/FOXO1 Double Nickase Plasmid (h) and FKHR/FOXO1 Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting FOXO1. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: FKHR/FOXO1 Antibody (C-9): sc-374427
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
FKHR/FOXO1 Double Nickase Plasmid (h) | sc-400137-NIC | 20 µg | $410.00 | |||
FKHR/FOXO1 Double Nickase Plasmid (h2) | sc-400137-NIC-2 | 20 µg | $410.00 |
FOXO1 (FKHR) encodes a forkhead box transcription factor that integrates insulin/IGF-1 and PI3K–AKT signaling with cellular programs controlling metabolism, oxidative stress responses, cell-cycle arrest, and apoptosis. AKT-dependent phosphorylation regulates FOXO1 nuclear-cytoplasmic shuttling and transcriptional output, linking nutrient status to gene expression programs such as gluconeogenesis and autophagy. FOXO1 also interfaces with TGF-β/SMAD and MAPK pathways to modulate differentiation and tissue homeostasis. Dysregulated FOXO1 activity or localization is implicated in metabolic dysfunction and cancer biology, and FOXO1 genomic alterations such as fusion events are used to study oncogenic transcriptional reprogramming.
FKHR/FOXO1 Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the FOXO1 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within FOXO1. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt FOXO1 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of FOXO1-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.